The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II trial of combination nab-paclitaxel and pemetrexed in advanced solid tumor patients (pts) with emphasis on non-small cell lung cancer (NSCLC).
Jonathan Riess
No relevant relationships to disclose
Cheryl Ho
Honoraria - Lilly
Angela M. Davies
No relevant relationships to disclose
Derick Lau
No relevant relationships to disclose
Primo Lara
Consultant or Advisory Role - Agennix; Genentech; Immunogen; Medivation; Pfizer; Teva
Honoraria - Elsevier
Research Funding - Genentech/Roche; GlaxoSmithKline; Janssen Oncology; Millennium; NCI
Helen K. Chew
No relevant relationships to disclose
Laurel Beckett
No relevant relationships to disclose
Randeep S. Sangha
No relevant relationships to disclose
Philip C. Mack
No relevant relationships to disclose
David R. Gandara
Consultant or Advisory Role - Celgene